VK2735
Neutral, BioHarmony verdict
BioHarmony score 5.3 out of 10
VK2735 is an investigational dual GLP-1 and GIP receptor agonist from Viking Therapeutics that produced about 14.7 percent weight loss at 13 weeks in its peer-reviewed VENTURE Phase 2 injectable trial, per Bays 2026. Every dataset is 13 weeks or shorter and it is not approved.
Read full reportWhat is VK2735?
VK2735 is an investigational weight-loss and metabolic drug from Viking Therapeutics that activates two gut hormone receptors at once, the GLP-1 receptor and the GIP receptor. That dual-incretin design is the exact same mechanism behind tirzepatide, the approved drug sold as Mounjaro and Zepbound. The whole reason I'm scoring VK2735 is that it sits at the earliest stage of the next-generation incretin batch, and its early numbers are strong enough to take seriously. In its one peer-reviewed trial, the injectable form drove about 14.7 percent weight loss in just 13 weeks. That is genuinely competitive with the best in class, and I dig into that study in the Upside Rationale below.
From the BioHarmony report, reviewed Sep 8, 2026.
Saved on this device only.
How it is thought to work
Activates GLP-1 and GIP receptors together for appetite suppression, slowed gastric emptying, and glucose-dependent insulin release
Safety watch-outs
- Severe or persistent abdominal pain, especially radiating to the back (possible pancreatitis): stop and seek care.
- A neck lump, hoarseness, or trouble swallowing (the class carries a thyroid C-cell tumor warning): stop and consult a clinician.
- Severe, ongoing vomiting or dehydration: stop and rehydrate, and seek care if it does not settle.
- Any unverified or research-chemical-grade source: do not inject or ingest, since purity and contamination are unknown.
Full risk profile in the BioHarmony report.
Dosing as published
Source-reported figures only. This page does not calculate a personal dose.
No approved-label or study protocol is recorded for VK2735 yet.
More reported protocols
MembersMembers can compare additional reported doses, schedules, and preparation notes.
Trust & sourcing
- Last revieweddone
- Next reviewupcoming
Viking Therapeutics reports that subcutaneous VK2735 is in phase 3 development for obesity, with oral VK2735 also advancing.
Primary sources
- Viking completes enrollment in phase 3 VANQUISH-2 trial Viking Therapeutics,
- VK2735 for weight management phase 3 ClinicalTrials.gov, U.S. National Library of Medicine,
Related peptides for weight & metabolic
- 6.1TirzepatideTirzepatide is a once-weekly subcutaneous dual GIP plus GLP-1 receptor agonist with unusually large weight-loss and glycemic effects.
- 6.0MOTS-cMOTS-c is a 16-amino-acid mitochondrial-derived peptide discovered in Lee 2015 that activates AMPK through the folate and purine pathway.
- 6.0TesamorelinTesamorelin is a stabilized GHRH analog that reduced visceral adipose tissue in the landmark Falutz 2007 HIV lipodystrophy Phase 3 trial and has newer support for…
- 5.9Semaglutide (GLP-1 Agonist)Semaglutide is a prescription GLP-1 receptor agonist that produced 14.9% mean weight loss in STEP-1 and cut 3-point MACE by 20% in SELECT, but the 5.5-6.0/10 score holds…
The Ultimate Peptides Guide
Spot stronger candidates, weak evidence, and seller red flags before you buy.